GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by adm...

Full description

Bibliographic Details
Main Authors: Daiki Kato, Tomonori Yaguchi, Takashi Iwata, Yuki Katoh, Kenji Morii, Kinya Tsubota, Yoshiaki Takise, Masaki Tamiya, Haruhiko Kamada, Hiroki Akiba, Kouhei Tsumoto, Satoshi Serada, Tetsuji Naka, Ryohei Nishimura, Takayuki Nakagawa, Yutaka Kawakami
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2020-03-01
Series:eLife
Subjects:
adverse effects
anti-PD-1 Ab
combination immunotherapy
CAR-T cells
solid tumor
Online Access:https://elifesciences.org/articles/49392

Internet

https://elifesciences.org/articles/49392

Similar Items